Direct and indirect regulation of the tumor immune microenvironment by VEGF

Abstract

Vascular endothelial growth factor-A (VEGF) is the predominant angiogenic factor that is expressed in solid tumors. Besides its critical function in mediating tumor angiogenesis, multiple studies have demonstrated that VEGF also contributes to tumor immunosuppression. VEGF interferes with immune cell trafficking indirectly by promoting a vascular immune barrier through VEGF receptor (VEGFR) activity on endothelial cells. However, VEGFRs are also expressed on multiple immune cell types, including T cells (effector T cells, Tregs) and myeloid cells (DCs, TAMs, MDSCs), where VEGF can have direct effects on immune cell phenotype and function. Thus, it is not surprising that strategies targeting VEGF/VEGFRs have shown efficacy in alleviating tumor-associated immunosuppression and have been combined with immunotherapies, especially immune checkpoint blockade. In this review, we discuss the direct and indirect effects of VEGF on the immunosuppressive tumor microenvironment with particular focus on the direct regulation of immune cells through VEGFR2 activity. We also summarize preclinical and clinical observations of combining antiangiogenesis agents with immunotherapies for the treatment of solid tumors.

Reiterative modeling of combined transcriptomic and proteomic features refines and improves the prediction of early recurrence in squamous cell carcinoma of head and neck

“…ERRFI1 (ERBB receptor feedback inhibitor 1, also called MIG-6) negatively regulates EGFR-family receptors by inhibiting their autophosphorylation, but also acts by upregulating glucose uptake and glycolysis to aid tumor cell growth [39]. KDR (also called VEGFR2) is a recptor for VEFFA, VEGFC and VEGFD (note that VEGFA mRNA was also identified in our study) and is expressed on endothelial cells to promote angiogenesis and on immune cells to influence the immunosuppressive microenvironment [40]. SERPINE1 (also called PAI, plasmogen activator inhibitor 1) is a serine protease inhibitor that promotes squamous cell migration during wound repair, aids cancer cell survival, has pro-angiogenic effects and influences cancer-associated immunosuppression, and is a robust and reliable prognostic indicator for many cancer types [41].…”

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells

“…Angiogenic factors are produced by tumor cells and by other cell types such as: endothelial cells, fibroblasts, smooth muscle cells/pericytes, and infiltrating immune cells; they initiate the angiogenic process by activating endothelial cells and induction of the angiogenic switch 4 , 6 . Vascular endothelial growth factor (VEGF) is involved in endothelial cell activation and is the major tumor angiogenesis factor 6 , 7 . Inhibiting endothelial cell growth and survival through the use of endothelial-specific integrin inhibitors, or inhibiting endothelial cell invasion using specific inhibitors of MMPs are used approaches to hinder tumor growth and spread 8 .…”

3D printing to construct in vitro multicellular models of melanoma

“…It is well known that blood vessels play an important role in tumorigenesis and that angiogenesis is a prerequisite for tumor metastasis and spread (Zhang & Brekken, 2022). Vascular endothelial growth factor (VEGF) plays a central role in angiogenesis by stimulating neointima growth and vascular abnormalities (e.g., hypertension), thereby preventing the transfer of antitumor drugs and blocking the immune response against tumors, among other important ways to promote tumor growth (You & Stallcup, 2017).…”